Cambridge Innovation leads £4m round for Inviata

Co-investment was provided by Imperial Innovations and Johnson & Johnson Development Corporation.

The business will use the fresh funding to develop its cancer monitoring technology.

CIC backs high-growth technology companies in the Cambridge area via its £50m Cambridge Cluster fund. The VC manages a vehicle affiliated with the University of Cambridge and aims to support businesses in the Cambridge area. Its maiden investment occurred in August this year, with the Inviata transaction marking its first foray into the life sciences sector.

Company
Based in Cambridge, Inviata has developed a new technique that allows information regarding cancerous tumours to be gained quickly from a blood test. The clinical cancer genomics company is currently developing a non-invasive liquid biopsy that can be used to assess a tumour's response to treatment by detecting the fragments of DNA released by tumours into the blood stream. 

People
Peter Keen is the CEO and Victor Christou is a senior investment director at CIC.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Early-stage
• United Kingdom